The MDT-BRIDGE trial's 142-patient neoadjuvant durvalumab dataset introduces a multidisciplinary reassessment architecture ...

Medrio's Early Adopter Program offers three tiers of discounted access to clinical trial software, with Level 2 participants ...

Kos Biotechnology Partners funds Golden Age Health to accelerate rare disease access in Asia, closing treatment delays for ...

Citius Oncology reports preliminary LYMPHIR unit sales and vial orders for Q4 2026, signaling commercial momentum in the ...

EIK1001 achieves 63.1% response rate in untreated stage 4 lung cancer, with strong disease control across histology subtypes ...

ORKA-001 achieves 61% complete skin clearance in Phase 2b psoriasis trial, with potential for once-yearly dosing in ...

RELATIVITY-047's 5-year survival data and LAG-3-high CD8+ T cell biomarker findings signal a shift in how immuno-oncology ...

NHWD-870 HCl achieves 45% response rate in thoracic NUT carcinoma, nearly doubling the overall cohort's 30% rate in advanced ...

Tarlatamab plus durvalumab cuts death risk 58% in first-line small cell lung cancer, extending median overall survival to ...

Sefaxersen achieves 43% proteinuria reduction in Phase 3 IgA Nephropathy Study, targeting disease mechanisms beyond standard care in kidney disease treatment.

Lilly's sofetabart mipitecan achieves 79% response rate in platinum-sensitive ovarian cancer patients, including those with prior PARP inhibitor exposure.

FDA approves subcutaneous SKYRIZI for Crohn's disease induction, allowing at-home treatment. Phase 3 data showed 74% of biologic-naive patients reached clinical ...